Illumina (XSWX:ILMN) 3-Year RORE % : -136.98% (As of Mar. 2026)


XSWX:ILMN Illumina Inc XSWX:ILMN
76 GF Score
Price CHF143.95
GF Value CHF105.51
! 7 Warning Signs
View Full Analysis

What is Illumina 3-Year RORE %?

Illumina XSWX:ILMN -0.79% 76 3-Year RORE % is -136.98 as of Mar. 2026. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF105.51. The stock has 7 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Illumina ranks worse than 95.54% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Illumina's 3-Year RORE % for the quarter that ended in Mar. 2026 was -136.98%.

The industry rank for Illumina's 3-Year RORE % or its related term are showing as below:

XSWX:ILMN's 3-Year RORE % is ranked worse than
95.54% of 202 companies
in the Medical Diagnostics & Research industry
Industry Median: -8.155 vs XSWX:ILMN: -136.98

Illumina  (XSWX:ILMN) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Illumina 3-Year RORE % Related Terms


Illumina 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Illumina's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina 3-Year RORE % Chart

Illumina Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.21 169.34 38.47 -49.34 -119.65

Illumina Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.32 -89.88 -86.79 -119.65 -136.98

XSWX:ILMN vs MTD, DGX, LH: 3-Year RORE % Comparison

For the Diagnostics & Research subindustry, Illumina's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina 3-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Illumina's 3-Year RORE % falls into.


XSWX:ILMN
76GF Score
Illumina Inc XSWX:ILMN
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Illumina 3-Year RORE % Calculation

Illumina's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 4.398--7.286 )/( -8.53-0 )
=11.684/-8.53
=-136.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -136.98 mean?
Illumina (XSWX:ILMN) has a 3-Year RORE % of -136.98 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Illumina and its competitors. According to the industry distribution chart, Illumina ranks #193 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 95.5%.
Is Illumina's 3-Year RORE % too high?
Illumina's current 3-Year RORE % is -136.98. Based on the distribution chart, Illumina ranks #193 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's 3-Year RORE % compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #193 out of 202 companies for 3-Year RORE %. This places Illumina in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Illumina and its competitors. Illumina's current 3-Year RORE % is -136.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current 3-Year RORE % of -136.98. The stock's GF Value™ is CHF105.51, compared to a current price of CHF143.95 — trading 36.4% above its estimated fair value. The current 3-Year RORE % is -136.98. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current 3-Year RORE % is -136.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Illumina (XSWX:ILMN) Overvalued in 2026?

Based on GuruFocus' analysis, Illumina stock appears to be overvalued. The current stock price of CHF143.95 is trading 36.4% above its estimated GF Value™ of CHF105.51.

Key valuation signals for XSWX:ILMN:

  • 3-Year RORE %: -136.98
  • GF Value™: CHF105.51 vs. price of CHF143.95 (36.4% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Illumina Business Description

Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score

Get the complete analysis for XSWX:ILMN

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF143.95
Price
CHF105.51
GF Value